Mesothelin Targeted Cell Therapy for Solid Tumors Including Mesothelioma | Raffit Hassan, MD

Raffit Hassan, MD
Chief, Thoracic and GI Malignancies Branch
Center for Cancer Research, National Cancer Institute, NIH

Dr. Raffit Hassan is a Senior Investigator and Chief of the Thoracic and GI Malignancies Branch at the National Cancer Institute, NIH. He has played a pivotal role in validating the tumor differentiation antigen mesothelin as a target for cancer therapy and development of mesothelin targeted immunotherapy. His current research focus is on developing effective mesothelin directed adoptive cellular therapies to treat patients with treatment refractory solid tumors including mesothelioma. The Hassan lab also studies the genetics of mesothelioma and is leading a prospective trial of early cancer detection in patients and their family members with germline mutations in the BAP1 cancer pre-disposition gene. Dr. Hassan is a recipient of the ASCO Career Development Award, the Wagner Award from the International Mesothelioma Interest Group and the Pioneer Award from the Mesothelioma Foundation.

JOIN HERE!

Dr. Hassan’s Objectives:

At the end of the presentation, participants will be able to do the following

• Analyze Mesothelin as target for cell therapy
• Explain CAR T therapy for solid tumors
• Revise developing better CAR T cells for solid tumors

Faculty Disclosure

Dr. Hassan has indicated that he has the following financial relationships:

Adaptimmune / Grant or Research Support

Planning Committee Disclosure

Dr. Lekakis has indicated that he has no relevant financial relationships with commercial interests.

Target Audience

Faculty, Primary Care Physicians, APRNs, PharmD

Accreditation

The University of Miami Leonard M. Miller School of Medicine is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Credit Designation

The University of Miami Leonard M. Miller School of Medicine designates this live activity for a maximum of 1 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.